Skip to main content
. 2016 May-Jun;42(3):578–584. doi: 10.1590/S1677-5538.IBJU.2015.0256

Table 1. Clinical features and demographic characteristics of patients in three groups and comparison of all groups in term of POUR.

Group I (Placebo) Group II (Tamsulosin) Group III (Alfuzosin) ANOVA F Test (F) or chi-square test (X2) p value
Number of patients 60 60 60
Mean age±SD (year) 34.95±15.21 (18-67) 36.30±15.22 (18-69) 36.60±15.26 (18-68) F=0.200 0.819
Pre-operative urinary X2=0.196 0.995
Symptoms* 37 (61.6%) 38 (63.3%) 39 (65%)
No 16 (26.7%) 15 ( 25%) 15 (25%)
Mild Moderate 7 (11.7%) 7 (11.7%) 6 (10%)
Region of surgery
Inguinal 34 (56.7%) 36 (60%) 34 (56.7%)
Penile 6 (10%) 4 (6.7%) 5 (8.3%)
Scrotal 18 (30%) 19 (31.6%) 20 (33.3%)
Perineal 2 (3.3%) 1 (1.7%) 1 (1.7%)
Mean operation time±SD (minute) 48.58±12.69 (27-78) 52.28±13.34 (29-85) 53.63±13.72 (28-84) F=2.333 0.100
Number of patients with POUR 15(25%) 3(5%) 4(6.7%)
Comparison of Group I and Group II in term of POUR X2=9.412 0.002
Comparison of Group I and Group III in term of POUR X2=7.566 0.006
Comparison of Group II and Group III in term of POUR X2=1.52 0.694

*According to AUA (American Urological Association) symptom score.